IGI Logo

Below is quote on Cadila Healthcare Limited results by Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd   

Cadila Healthcare Limited reported numbers in line with market expectations.

Cadila revenue from operations for the quarter up by 15% YoY and 9% QoQ at ₹4025 crores, consolidated EBITDA up by 18% YoY at ₹933 crores. Company has reported higher than expected EBITDA margins at 23.2% up by 140 bps on QoQ. Company has reduced its net debt by ₹384 crores to ₹3112 crores and net debt will come down to ₹1000 crores after the sale of the animal healthcare segment.

Overall company has reported good set of numbers, domestic business has done well for the company up by 43% while USA business down by 37%, we expect domestic business to continue its momentum for next couple of quarters as company has gained the market share in anti-diabetic, anti-infective and nutraceuticals therapeutic areas on a YoY basis. Company has reported improvements in EBITDA margins also. We have a positive view on Cadila Healthcare Limited.

Above views are of the author and not of the website kindly read disclaimer